Retinal atrophy in multiple sclerosis is similar with extended versus standard interval natalizumab therapy
{{output}}
Background: Retinal ganglion cell + inner plexiform layer (GCIPL) atrophy reflects global neurodegeneration and disability in multiple sclerosis. Extended interval dosing (EID; every 5-8 weeks) natalizumab reduces progressive mul... ...
